Evidence map›Paper›PMID 42221086›Full record

ReviewFrontiers in medicine2026

Emerging therapeutic targets in non-infectious uveitis and scleritis.

Usanee Tungsattayathitthan, Debra A Goldstein, Timothy M Janetos

Abstract readReview
In one paragraph

Review in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Usanee TungsattayathitthanDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Debra A GoldsteinDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.
Timothy M JanetosDepartment of Ophthalmology, Feinberg School of Medicine, Northwestern University, Chicago, IL, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-infectious uveitis and scleritis are significant causes of visual impairment, and currently available targeted and effective therapeutic options remain limited. Multiple immunologic pathways are currently under investigation and targeted therapeutics have the potential to change the treatment landscape and improve visual outcomes. This review synthesizes potential upcoming local and systemic treatments for non-infectious uveitis and scleritis with a focus on therapeutics with human data, noting those with the most promising evidence, and areas of gaps in research.

Indexed as

biologicsscleritistherapeuticstreatmentuveitis

Identifiers

PMID42221086
PMCPMC13219372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.